Hemo Organic Ltd Stock Price Today (NSE: HEMORGANIC)
Fundamental Score
Hemo Organic Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Hemo Organic Ltd share price today is ₹15.30, up +0.00% on NSE/BSE as of 19 February 2026. Hemo Organic Ltd (HEMORGANIC) is a Small-cap company in the Trading & Distributors sector with a market capitalisation of ₹4.15 (Cr). The 52-week high for HEMORGANIC share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 34.62x, HEMORGANIC is currently trading below its industry average P/E of 35.45x.
Hemo Organic Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Hemo Organic Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Financial Analysis of Hemo Organic Share Price
The Trading & Distributors sector is often characterized by relatively thin margins and intense competition, making efficient capital allocation crucial for long-term success. Analyzing the current scenario, the Hemo Organic share price stands at ₹14.99. A key metric to consider is the Price-to-Earnings (PE) ratio, which currently sits at 34.62. This suggests that the market has relatively high expectations for future earnings growth compared to the current earnings, which is important to understand.
However, the Return on Capital Employed (ROCE) paints a different picture. At 2.65%, Hemo Organic's ROCE is significantly lower than what investors might expect given its PE ratio. A low ROCE indicates that the company isn't generating substantial returns from its invested capital. This has a direct impact on the company's ability to build a strong economic moat. A robust moat, typically characterized by factors like brand strength, cost advantages, or high switching costs, allows a company to sustain its competitive advantage. The current ROCE suggests limited scope for a durable competitive edge at this stage.
When comparing Hemo Organic to its peers, such as
Prismx Global Ventures Ltd, we can examine various factors contributing to their respective performances. Beyond just the numbers, qualitative aspects such as the perceived management quality and strategic vision play a crucial role in influencing investor sentiment. A strong management team can effectively navigate industry challenges, innovate, and create value for shareholders, which can ultimately affect the valuation multiple assigned by the market.WARDWIZARD HEALTHCARE LIMITED and Ganon Products Ltd also operate within this competitive landscape, and it is important to analyze their capital efficiency and growth trajectories to get a complete peer comparison. The low ROCE raises questions about long-term value creation. Understanding these factors is crucial for contextualizing the Hemo Organic share price and its potential for future growth. This analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Hemo Organic Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of HEMORGANIC across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (62.50%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (54.93% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (58.49% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (58.49% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Suboptimal ROCE (2.65%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-15.92%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Negative Free Cash Flow (₹-1.45 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (16.85%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Hemo Organic Ltd Financial Statements
Comprehensive financial data for Hemo Organic Ltd including income statement, balance sheet and cash flow
About HEMORGANIC (Hemo Organic Ltd)
Hemo Organic Ltd (HEMORGANIC) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Trading & Distributors sector with a current market capitalisation of ₹4.15 (Cr). Investors tracking HEMORGANIC share price can monitor key metrics including P/E ratio, promoter holding of 16.85%, and quarterly earnings growth.
Company Details
Key Leadership
HEMORGANIC Share Price: Frequently Asked Questions
What is the current share price of Hemo Organic Ltd (HEMORGANIC)?
As of 19 Feb 2026, 10:09 am IST, Hemo Organic Ltd share price is ₹15.30. The HEMORGANIC stock has a market capitalisation of ₹4.15 (Cr) on NSE/BSE.
Is HEMORGANIC share price Overvalued or Undervalued?
HEMORGANIC share price is currently trading at a P/E ratio of 34.62x, compared to the industry average of 35.45x. Based on this relative valuation, the Hemo Organic Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of HEMORGANIC share price?
The 52-week high of HEMORGANIC share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Hemo Organic Ltd share price?
Key factors influencing HEMORGANIC share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Hemo Organic Ltd a good stock for long-term investment?
Hemo Organic Ltd shows a 5-year Profit Growth of 58.49% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of N/A before investing in HEMORGANIC shares.
How does Hemo Organic Ltd compare with its industry peers?
Hemo Organic Ltd competes with major peers in the Trading & Distributors. Investors should compare HEMORGANIC share price P/E of 34.62x and ROE of N/A% against the industry averages to determine competitive standing.
What is the P/E ratio of HEMORGANIC and what does it mean?
HEMORGANIC share price has a P/E ratio of 34.62x compared to the industry average of 35.45x. Investors pay ₹35 for every ₹1 of annual earnings.
How is HEMORGANIC performing according to Bull Run's analysis?
HEMORGANIC has a Bull Run fundamental score of 38.9/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does HEMORGANIC belong to?
HEMORGANIC operates in the Trading & Distributors industry. This classification helps understand the competitive landscape and sector-specific trends affecting Hemo Organic Ltd share price.
What is Return on Equity (ROE) and why is it important for HEMORGANIC?
HEMORGANIC has an ROE of N/A%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Hemo Organic Ltd generates profits from shareholders capital.
How is HEMORGANIC debt-to-equity ratio and what does it indicate?
HEMORGANIC has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk.
What is HEMORGANIC dividend yield and is it a good dividend stock?
HEMORGANIC offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Hemo Organic Ltd shares.
How has HEMORGANIC share price grown over the past 5 years?
HEMORGANIC has achieved 5-year growth rates of: Sales Growth 54.93%, Profit Growth 58.49%, and EPS Growth 58.49%.
What is the promoter holding in HEMORGANIC and why does it matter?
Promoters hold 16.85% of HEMORGANIC shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Hemo Organic Ltd.
What is HEMORGANIC market capitalisation category?
HEMORGANIC has a market capitalisation of ₹4 crores, placing it in the Small-cap category.
How volatile is HEMORGANIC stock?
HEMORGANIC has a beta of N/A. A beta > 1 suggests the Hemo Organic Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is HEMORGANIC operating profit margin trend?
HEMORGANIC has a 5-year average Operating Profit Margin (OPM) of -15.92%, indicating the company's operational efficiency.
How is HEMORGANIC quarterly performance?
Recent quarterly performance shows Hemo Organic Ltd YoY Sales Growth of N/A% and YoY Profit Growth of 62.50%.
What is the institutional holding pattern in HEMORGANIC?
HEMORGANIC has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Hemo Organic Ltd stock.